Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Track (GIT) Symptoms in Thailand (GerdQ)

AstraZeneca

Status: Completed

Conditions: Upper GIT Symptoms

Study type: Observational

Funder types: Industry

Identifiers

NCT00999063

NIS-GTH-NEX-2009/1

Details and patient eligibility

About

This is a prospective , epidemiological, multi-centre, phase IV study, approximately 5,000 patients who suffer with upper gastrointestinal tract symptoms. Each patient will be assessed for GERD with GerdQ Thai Version.

Enrollment: 4,108 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Provision of informed consent prior to any study specific procedures
• Female or male aged at least 18 years
• Patient must be having symptoms suggestive of upper gastrointestinal tract symptoms such as heart burn/ regurgitation

Exclusion criteria

• Involvement in the planning and /or conduct of the study (applies to both AstraZeneca staff and /or staff at study site
• Participation in a clinical study(excluding non-interventional study or registry) during the last 3 months